| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | 10%+ Owner | Common Stock | 7.69M | $146M | $19.00 | Jun 28, 2021 | Indirect |
| Savara Inc | 10%+ Owner | Common Stock | 24.5M | $109M | $4.45 | Jul 17, 2023 | Indirect |
| Korro Bio, Inc. | 10%+ Owner | Common Stock | 1.09M | $61.1M | $56.00 | Apr 22, 2024 | Indirect |
| Trevi Therapeutics, Inc. | 10%+ Owner | Pre-Funded Warrants | 3M | $5.7M | $1.90 | Apr 11, 2022 | Indirect |
| Trevi Therapeutics, Inc. | 10%+ Owner | Common Stock | 949K | $1.92M | $2.02 | Apr 11, 2022 | Indirect |
| Metacrine, Inc. | 10%+ Owner | Common Stock | 2.56M | $1.2M | $0.47 | Dec 22, 2021 | Indirect |
| Mirum Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 114 | $3.2K | $28.04 | Jun 13, 2023 | Indirect |
| Trevi Therapeutics, Inc. | 10%+ Owner | 3.5-Year Common Stock Warrant | 1.85M | Oct 18, 2021 | Indirect | ||
| Trevi Therapeutics, Inc. | 10%+ Owner | 7-Year Common Stock Warrant | 1.85M | Oct 18, 2021 | Indirect | ||
| NeueHealth, Inc. | 10%+ Owner | Warrant (Right to Buy) | 371K | Apr 8, 2024 | Indirect | ||
| Allakos Inc. | Director | Stock Option (Right to buy) | 41K | May 24, 2024 | Direct | ||
| Akouos, Inc. | 10%+ Owner | Common Stock | 0 | $12.50 | Nov 30, 2022 | Indirect | |
| GENOCEA BIOSCIENCES, INC. | 10%+ Owner | Common Stock | 0 | $1.25 | May 25, 2022 | Indirect | |
| Monte Rosa Therapeutics, Inc. | 10%+ Owner | Series A-2 convertible preferred stock | 0 | Jun 28, 2021 | Indirect | ||
| Monte Rosa Therapeutics, Inc. | 10%+ Owner | Series B convertible preferred stock | 0 | $2.00 | Jun 28, 2021 | Indirect | |
| Monte Rosa Therapeutics, Inc. | 10%+ Owner | Series C convertible preferred Stock | 0 | $2.96 | Jun 28, 2021 | Indirect | |
| Trillium Therapeutics Inc. | Director | Common Shares | 0 | Nov 17, 2021 | Indirect | ||
| Trillium Therapeutics Inc. | Director | Series II Non-Voting Convertible First Preferred Shares | 0 | Nov 17, 2021 | Indirect | ||
| Trillium Therapeutics Inc. | Director | Stock Option (Right to Buy) | 0 | Nov 17, 2021 | Direct | ||
| Trillium Therapeutics Inc. | Director | Warrant to Purchase Common Shares | 0 | Nov 17, 2021 | Indirect | ||
| Trillium Therapeutics Inc. | Director | Warrant to Purchase Series II Preferred Shares | 0 | Nov 17, 2021 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | 10%+ Owner |
| ALLK | Allakos Inc. | May 24, 2024 | 1 | $0 | 4 | May 29, 2024 | Director |
| KRRO | Korro Bio, Inc. | Apr 22, 2024 | 1 | $1M | 4 | Apr 24, 2024 | 10%+ Owner |
| NEUE | NeueHealth, Inc. | Apr 8, 2024 | 3 | $0 | 4 | Apr 10, 2024 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Dec 19, 2023 | 1 | $0 | 4 | Dec 21, 2023 | 10%+ Owner |
| FREQ | Korro Bio, Inc. | Nov 3, 2023 | 0 | $0 | 3 | Nov 7, 2023 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Oct 31, 2023 | 1 | $0 | 4 | Nov 2, 2023 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Sep 15, 2023 | 1 | $0 | 4 | Sep 19, 2023 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Aug 11, 2023 | 1 | $0 | 4 | Aug 16, 2023 | 10%+ Owner |
| SVRA | Savara Inc | Jul 17, 2023 | 1 | $1M | 4 | Jul 19, 2023 | 10%+ Owner |
| MIRM | Mirum Pharmaceuticals, Inc. | Jun 13, 2023 | 4 | $0 | 4 | Jun 15, 2023 | 10%+ Owner |
| ALLK | Allakos Inc. | May 25, 2023 | 1 | $0 | 4 | May 30, 2023 | Director |
| AKUS | Akouos, Inc. | Nov 30, 2022 | 1 | $0 | 4 | Dec 2, 2022 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Oct 17, 2022 | 2 | $138M | 4 | Oct 19, 2022 | 10%+ Owner |
| ALLK | Allakos Inc. | Sep 21, 2022 | 2 | $20M | 4 | Sep 23, 2022 | Director |
| ALLK | Allakos Inc. | May 25, 2022 | 1 | $0 | 4 | May 27, 2022 | Director |
| GNCA | GENOCEA BIOSCIENCES, INC. | May 24, 2022 | 2 | -$751K | 4 | May 26, 2022 | 10%+ Owner |
| TRVI | Trevi Therapeutics, Inc. | Apr 11, 2022 | 3 | $12.5M | 4 | Apr 13, 2022 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Jan 3, 2022 | 2 | $200M | 4 | Jan 5, 2022 | 10%+ Owner |
| MTCR | Metacrine, Inc. | Dec 10, 2021 | 3 | -$494K | 4 | Dec 27, 2021 | 10%+ Owner |
| TRIL | Trillium Therapeutics Inc. | Nov 17, 2021 | 5 | $0 | 4 | Nov 19, 2021 | Director |
| TRVI | Trevi Therapeutics, Inc. | Oct 18, 2021 | 3 | $0 | 4 | Oct 19, 2021 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Jun 28, 2021 | 12 | $35M | 4 | Jun 30, 2021 | 10%+ Owner |
| GLUE | Monte Rosa Therapeutics, Inc. | Jun 28, 2021 | 7 | $20M | 4 | Jun 30, 2021 | 10%+ Owner |
| BHG | Bright Health Group Inc. | Jun 24, 2021 | 0 | $0 | 3 | Jun 24, 2021 | 10%+ Owner |
| GLUE | Monte Rosa Therapeutics, Inc. | Jun 23, 2021 | 0 | $0 | 3 | Jun 23, 2021 | 10%+ Owner |
| ALLK | Allakos Inc. | May 25, 2021 | 1 | $0 | 4 | Oct 14, 2021 | Director |